GTC Biotherapeutics (fka GTCB)

[aslan2772]

This is good news, as expected. Congrats longs! The next hurdle for this trial is immunogenicity. I don't expect any significant problems there, but it is a bigger hurdle than efficacy, IMHO (only bad luck or inadequate trial design could have interfered with reaching the primary endpoint). GTCB has moved a step closer to profitability, which is fundamentally important since cash has long been their biggest concern.

Cheers.